Checkmate 227 is an open-label phase III trial of upfront Nivolumab (+chemotherapy in those with PDL-1 < 1%) versus Nivolumab plus Ipilimumab versus chemotherapy alone (1:1:1) in stage IV or recurrent NSCLC with high mutational burden [104]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.